These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 8670046)

  • 21. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
    Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
    Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation.
    Gagel RF
    Endocrinology; 1996 May; 137(5):1509-11. PubMed ID: 8612478
    [No Abstract]   [Full Text] [Related]  

  • 23. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
    Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
    Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncological implications of RET gene mutations in Hirschsprung's disease.
    Sijmons RH; Hofstra RM; Wijburg FA; Links TP; Zwierstra RP; Vermey A; Aronson DC; Tan-Sindhunata G; Brouwers-Smalbraak GJ; Maas SM; Buys CH
    Gut; 1998 Oct; 43(4):542-7. PubMed ID: 9824583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [One gene--four diseases: on the importance of mutations in the ret gene in MEN 2A, MEN 2B, Hirschsprung disease and medullary thyroid carcinoma].
    Fehmann HC; Göke B
    Z Gastroenterol; 1994 Jul; 32(7):416-7. PubMed ID: 7975780
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
    Pasini B; Rossi R; Ambrosio MR; Zatelli MC; Gullo M; Gobbo M; Collini P; Aiello A; Pansini G; Trasforini G; degli Uberti EC
    Surgery; 2002 Apr; 131(4):373-81. PubMed ID: 11935126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
    Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
    EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
    Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
    Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease.
    Borst MJ; VanCamp JM; Peacock ML; Decker RA
    Surgery; 1995 Apr; 117(4):386-91. PubMed ID: 7716719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
    Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genes and genetics in Hirschsprung's disease].
    Maas SM; Brooks AS; Hennekam RC; Heydendael VM; Wijburg FA; Hofstra RM
    Ned Tijdschr Geneeskd; 1999 Jun; 143(26):1352-6. PubMed ID: 10416491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes.
    Fernández RM; Antiñolo G; Eng C; Borrego S
    Hum Mutat; 2003 Nov; 22(5):412-5. PubMed ID: 14517954
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
    Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
    Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.